Clarify the science
What must the evidence establish?Define the intended use, what is demonstrated, and which uncertainties matter to the next decision.
Evidence & developmentTHE CENTRAL CLARUS FRAMEWORKValue Inflection
Value Inflection
Engineering.
Work backward from the next consequential decision. Align the evidence, access pathway, execution, and capital needed to make that decision credible.
A strategic planning lens developed by BioClarus Consulting.
THREE CONNECTED QUESTIONS
From evidence to a usable decision.
Quantify the opportunity
What must change for adoption?Map the use case, delivery constraints, access pathway, operating assumptions, and resource dependencies.
Delivery & enabling technologyCommunicate the value
What can stakeholders decide?Translate supported evidence into a coherent milestone narrative, with visible risks, ownership, and next steps.
Access & commercial valueRESEARCH AND BIOCLARUS PERSPECTIVES
20 framework articlesPut the framework to work.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
The cancer-vaccine option: finance the evidence before counting the payment
Merck–Moderna’s collaboration provides the timeline; a separate cash model tests option exercise, delay, settlement and the no-payment branch.
ClarusBIOTECH REVIEWValue Inflection EngineeringEditorial feature
The Medicines We Never Get: Why Promising Science Fails to Reach Patients
Follow the decisions between a promising result and completed care—and distinguish scientific failure from avoidable execution gaps.
ClarusBIOTECH REVIEWValue Inflection EngineeringHypothetical consulting case
Clinical authorization and freedom to operate are separate milestones
The CRISPR patent appeal frames a hypothetical rights map, licensing sensitivity and IP diligence gate.
![A development-stage transaction has two price perimeters. Announced equity value: 4.9; Net of estimated cash: 4.6. USD billions. Vertex–Alpine agreement [1]; not two independent purchases.](/images/consulting/alpine-povetacicept-acquisition-next-readout-record.svg)
ClarusBIOTECH REVIEWValue Inflection EngineeringHypothetical consulting case
From Alpine to the next readout: define what the acquisition price did not resolve
A development-stage acquisition and a company-reported upcoming review date frame a fictional option-value model.
ClarusBIOTECH REVIEWValue Inflection EngineeringHypothetical consulting case
Buying an oncology platform does not buy a completed integration
Pfizer–Seagen provides transaction context for a fictional buyer’s integration reserve and portfolio gates.
![Announced 2023 collaboration payment categories. Upfront: 4; Continuation: 1.5; Maximum sales milestones: 16.5. USD billions. Three-asset deal [1]; contingent ceiling is not received cash.](/images/consulting/adc-license-headline-value-fundable-cash-record.svg)
ClarusBIOTECH REVIEWValue Inflection EngineeringHypothetical consulting case
The $22 billion headline is not the cash available to develop an ADC
A major ADC collaboration and a recent filing setback frame staged licensing, dilution and evidence-linked funding.
ClarusBIOTECH REVIEWValue Inflection EngineeringHypothetical consulting case
A royalty can finance the next mission—or be sold to fund it sooner
Cystic Fibrosis Foundation venture philanthropy frames a hypothetical royalty-retention and monetization decision.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
The biotech value curve: define what changes at each evidence gate
A numerical framework for understanding why a milestone may change value—and why the calendar alone does not.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
Biotech partnering: qualify the decision before building the contact list
Turn a leadership directory into a dated, evidence-based partnering process with measurable progression.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
The founder translation gap: turn a scientific signal into a decision brief
A practical architecture for communicating clinical meaning, financing exposure and the work required for adoption.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
AI value inflection: from technical promise to measurable enterprise value
A decision framework for separating clinical evidence, regulatory credibility and usable economic returns.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
Read the deal structure: upfront value and contingent milestones are different
A large ADC collaboration illustrates why maximum announced consideration should be decomposed before it enters a value narrative.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
Capital readiness: connect runway to the next credible evidence package
Recent industry financing data show why an aggregate recovery does not remove the need for company-level capital discipline.
ClarusBIOTECH REVIEWValue Inflection EngineeringEvidence synthesis · white paper
Engineer the Phase II decision: milestones should retire a defined uncertainty
Historical transition rates help frame the challenge; the program’s evidence must determine the actual go, revise, or stop decision.
ClarusBIOTECH REVIEWValue Inflection EngineeringHistorical case analysis
MiniMed 670G: a closed-loop claim needs one system evidence map
The 2016 hybrid system ties sensor, algorithm, pump, user tasks, and clinical evidence together.
ClarusBIOTECH REVIEWValue Inflection EngineeringHistorical case analysis
CureVac’s CVnCoV: platform promise needs candidate-level stop rules
HERALD and the 2021 rolling-review withdrawal illustrate a portfolio decision after an incomplete success.
ClarusBIOTECH REVIEWValue Inflection EngineeringHistorical case analysis
Cologuard: test sensitivity is the start of a screening pathway
The 2014 record connects a diagnostic metric to false positives, follow-up, and completed care.
ClarusBIOTECH REVIEWValue Inflection EngineeringHistorical case analysis
Exubera: field scale cannot repair an unaccepted proposition
Pfizer’s 2007 exit makes adoption testing and reversible deployment financially concrete.
ClarusBIOTECH REVIEWValue Inflection EngineeringHistorical case analysis
Aduhelm: an approval date was not an access-ready launch
The 2021–2024 sequence connects authorization, pricing, coverage, and the cost of stopping.
ClarusBIOTECH REVIEWValue Inflection EngineeringHistorical case analysis
Ivacaftor: engineer a milestone around a defined mutation
The original G551D program shows how a focused evidence package can make a decision consequential.
Build one integrated milestone plan.
| Planning question | Useful working output | Decision it supports |
|---|---|---|
| What is the next inflection thesis? | Milestone brief and stakeholder map | Agree what progress must demonstrate |
| What evidence remains missing? | Evidence-gap register and target product assumptions | Prioritize decision-relevant work |
| What blocks practical adoption? | Patient journey, access, and workflow map | Sequence capabilities and partnerships |
| What could break the plan? | Risk register, scenarios, and spending gates | Define contingencies and resource commitments |
| Who owns the next decision? | Accountable owners and a review cadence | Keep the roadmap coherent as evidence changes |
SOURCE NOTES
Grounded in BioClarus working papers.
- Value Inflection Engineering Launch Readiness Whitepaper · May 2026
- Sales Force Excellence Value Inflection Engineering Whitepaper · May 2026
- Transcriptome Value Inflection Engineering Whitepaper · May 2026
- Women’s-health drug–device strategic white paper · June 2026
- Alzheimer’s Brilliance Gala Diagnostics Value Inflection Whitepaper · May 2026, diagnostic milestone framework only
The articles are editorial adaptations, rather than full document reproductions. They omit confidential campaign details, numerical forecasts, and time-sensitive product or policy claims. They distinguish strategic interpretation from clinical evidence.